Based on a recent study, our team has published an article in “Pharmacoepidemiology and Drug Safety” titled, “Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse.” To access the full text, click here.
Understanding the spatial distribution of opioid abuse at the local level may facilitate public health interventions.
Using patient-level data from addiction treatment facilities in New Mexico from ASI-MV® Connect, we applied geographic information system in combination with a spatial scan statistics to generate risk maps of prescription opioid abuse and identify clusters of product- and compound-specific abuse. Prescribed opioid volume data was used to determine whether identified clusters are beyond geographic differences in availability.
Data on 24,452 patients residing in New Mexico was collected. Among those patients, 1779 (7.3%) reported abusing any prescription opioid (past 30 days). According to opioid type, 979 patients (4.0%) reported abuse of any hydrocodone, 1007 (4.1%) for any oxycodone, 108 (0.4%) for morphine, 507 (2.1%) for Vicodin® or generic equivalent, 390 (1.6%) for OxyContin®, and 63 (0.2%) for MS Contin® or generic equivalent. Highest rates of abuse were found in the area surrounding Albuquerque with 8.6 patients indicating abuse per 100 interviewed patients. We found clustering of abuse around Albuquerque (P=0.001; Relative Risk=1.35 and a radius of 146 km). At the compound level, we found that drug availability was partly responsible for clustering of prescription opioid abuse. After accounting for drug availability, we identified a second foci of Vicodin® abuse in the southern rural portion of the state near Las Cruces, NM and El Paso, Texas and bordering Mexico (RR=2.1; P=0.001).
A better understanding of local risk distribution may have implications for response strategies to future introductions of prescription opioids.
To obtain the full text, click here.